



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Keith L. Black
Appln. No. : 09/491,500
Filed : January 26, 2000
T.C/A.U. : 1632 ✓
Examiner : Anne Marie Faulk
Customer No. : 20786

Commissioner for Patents
Mail Stop RCE
P.O. Box 1450
Alexandria, VA 22313-1450

13. RCE/1600
November 4, 2003

Supplemental Documents

Sir:

Please accept the attached Supplemental Information Disclosure Statement inadvertently omitted from the Request for Continued Examination, Transmittal of Information Disclosure Statement, and Amendment under 37 CFR § 1.17(e), forwarded to the Patent and Trademark Office on October 29, 2003. We believe that no further fee is required with this submission, however if the Commissioner determines otherwise, he is hereby authorized to charge any associated fees to Deposit Account No. 11-0980.

Respectfully Submitted,

Rebecca J. Kaufman, Esq.
Reg. No. 44,819


King & Spalding
191 Peachtree St.
Atlanta, Georgia 30303
404-572-4600
404-572-5145 (fax)

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

11/4/03
Date

Susanne Hollinger



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Keith L. Black and Nagendra S. Ningaraj
Appln. No. : 09/491,500
Filed : October 29, 2003
T.C/A.U. : 1632
Examiner : Unassigned
Customer No. : 20786

Commissioner for Patents
Mail Stop Patent Application
P.O. Box 1450
Alexandria, VA 22313-1450

October 29, 2003

Transmittal of Supplemental Information Disclosure Statement

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Copies of all listed references are enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

This Transmittal is accompanied by a fee of \$180.00, for filing a Supplemental Information Disclosure. However, if the Examiner determines this fee is not accurate, the Commissioner is authorized to credit any overpayments or charge any additional fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,

Sherry M. Knowles, Esq.
Reg. No. 33,052

King & Spalding
191 Peachtree St.
Atlanta, Georgia 30303
404-572-3541

FORM PTO-1449, Adapted



LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO. 09/491,500	FILING DATE January 26, 2000
------------------	--------------------------	---------------------------------

APPLICANT Keith L. Black and Nagendra S. Ningaraj	GROUP 1632
--	---------------

U.S. PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	5,518,499	05/21/06	Agar			
AB	5,767,160	06/16/98	Kaesemeyer			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	Armstead, W.M., <i>Contribution of kca channel activation to hypoxic cerebrovasodilation does not involve NO</i> , <u>Brain Res</u> , 799:44-48 (1998). ABSTRACT ONLY.
AD	Barna, M., et al., <i>Activation of type III nitric oxide synthase in astrocytes following a neurotropic viral infection</i> , <u>Virology</u> , 223: 331-343 (1996).
AE	Becker, E.M., et al., <i>The vasodilator-stimulated phosphoprotein (VASP): target of YC-1 and nitric oxide effects in human and rate platelets</i> , <u>J Cardiovasc Pharmacol</u> , 35(3):390-7 (2000). ABSTRACT ONLY.
AF	Boje, K.M., <i>Inhibition of nitric oxide synthase attenuates blood-brain barrier disruption during experimental meningitis</i> , <u>Brain Research</u> , 720:75-83 (1996).
AG	Brandt, L., et al., <i>Effects of topical application of calcium antagonist (nifedipine) on feline cortical pial microvasculature under normal conditions and in focal ischemia</i> , <u>Journal of Cerebral Blood Flow and Metabolism</u> , 3:44-50 (1983).
AH	Brioni, J.D., et al., <i>Activators of soluble guanylate cyclase for treatment of male erectile dysfunction</i> , <u>International Journal of Impotence Research</u> , 14:8-14 (2002).
AI	Bychkov, R., et al. <i>Calicum-activated potassium channels and nitrate-induced vasodilation in human coronary arteries</i> , <u>J Pharmacol Exp Therap</u> , 285:293-8 (1998). ABSTRACT ONLY.
AJ	Chandran, S., et al., <i>Nitric oxide: concepts, current perspectives and future therapeutic implications</i> , <u>Indian Journal of Pharmacology</u> , 30:351-366 (1998).
AK	Chi, O.Z., et al. <i>Effect of inhibition of nitric oxide synthase on blood-brain barrier transport in focal cerebral ischemia</i> , <u>Pharmacology</u> , 48:367-373 (1994).
AL	Cloughesy, T.F., et al., <i>Pharmacological blood-brain barrier modification for selective drug delivery</i> , <u>Journal of Neuro-Oncology</u> , 26:125-132 (1995).
AM	Feelisch, M., <i>The use of nitric oxide donors in pharmacological studies</i> , <u>Naunyn-Schmiedeberg's Arch Pharmacol</u> , 358:113-122 (1998).
AN	Fukao, M., et al., <i>Cyclic GMP-dependent protein kinase activates cloned BKCa channels expressed in mammalian cells by direct phosphorylation at serine 1072</i> , <u>J Biol Chem</u> , 274(16):10927-35 (1999).
AO	Fukumura, D., et al., <i>Role of nitric oxide in angiogenesis and microcirculation in tumors</i> , <u>Cancer and Metastasis Reviews</u> , 17:77-89 (1998).
AP	He, P., et al., <i>cGMP modulates basal and activated microvessel permeability independently of [Ca²⁺]_i</i> , <u>Am J Physiol</u> , 274:H1865-74 (1998). ABSTRACT ONLY.
AQ	Herrera, G.M., et al., <i>Maintained vasodilatory response to cromakalim after inhibition of nitric oxide synthesis</i> , <u>J Cardiovasc Pharmacol</u> , 31:921-9 (1998). ABSTRACT ONLY

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO. 09/491,500	FILING DATE January 26, 2000
APPLICANT Keith L. Black and Nagendra S. Ningaraj		GROUP 1632

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	Holschermann, H., et al., <i>Dual role of cGMP in modulation of macromolecule permeability of aortic endothelial cells</i> , <u>Am J Physiol</u> , 272:H91-8 (1997). ABSTRACT ONLY.
AS	Hongli, X., et al., <i>Opening blood-brain-barrier by intracarotid infusion of papaverine in treatment of malignant cerebral glioma</i> , <u>Chinese Medical Journal</u> , 111(8):751-753 (1998).
AT	Hurst, R.D., et al., <i>Nitric oxide-induced perturbations in a cell culture model of the blood-brain barrier</i> , <u>Journal of Cellular Physiology</u> , 167:89-94 (1996).
AU	Inamura, T., et al., <i>Intracarotid histamine infusion increases blood tumour permeability in RG2 glioma</i> , <u>Neurological Research</u> , 16:125-128 (1994).
AV	Inamura, T., et al., <i>Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors</i> , <u>J Neurosurg</u> , 81:752-758 (1994).
AW	Janigro, D., et al., <i>Regulation of blood-brain barrier endothelial cells by nitric oxide</i> , <u>Circulation Research</u> , 75:528-528 (1994).
AX	Kimura, M., et al., <i>Responses of human basilar and other isolated arteries to novel nitric oxide donors</i> , <u>J Cardiovasc Pharmacol</u> , 32: 695-701 (1998). ABSTRACT ONLY.
AY	Koesling, D., <i>Modulators of soluble guanylyl cyclase</i> , <u>Naunyn-Schmiedeberg's Arch Pharmacol</u> , 358:123-126 (1998).
AZ	Liu, Y., et al., <i>Repeated, short-term ischemia augments bradykinin-mediated opening of the blood-tumor barrier in rats with RG2 glioma</i> , <u>Neurological Research</u> , 23:631-639 (2001).
BA	Lohse, M.J., et al., <i>Pharmacology of NO:cGMP signal transduction</i> , <u>Naunyn-Schmiedeberg's Arch Pharmacol</u> , 358:111-112 (1998).
BB	Matukado, T., et al., <i>Selective Increase in Blood Tumor Permeability by Calcium Antagonists in Transplanted Brain Tumors</i> , <u>Acta Neurochir</u> , 60: 403-405 (1994).
BC	Mayer, B., et al., <i>Nitric oxide synthases: catalytic function and progress toward selective inhibition</i> , <u>Naunyn-Schmiedeberg's Arch Pharmacol</u> , 358:127-133 (1998).
BD	Mayhan, W.G., <i>Role of nitric oxide in histamine-induced increases in permeability of the blood-brain barrier</i> , <u>Brain Research</u> , 743:70-76 (1996).
BE	Mayhan, W.G., et al., <i>Glutamate-induced disruption of the blood-brain barrier in rats</i> , <u>Stroke</u> , 27:965-970 (1996).
BF	Nakano, S., et al., <i>Increased brain microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide</i> , <u>Cancer Research</u> , 56:4027-4031 (1996).
BG	Ningaraj, N.S., et al., <i>Role of ATP-sensitive K⁺ channels in blood-brain tumor barrier permeability</i> , <u>Congress of Neurological Surgeons Annual Meeting</u> , 50 th Anniversary Celebration, September 23-28, 2000, Henry B. Gonzalez Convention Center, San Antonio, Texas, ABSTRACT No. 4309, p. 215.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449, Adapted




LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.		SERIAL NO. 09/491,500	FILING DATE January 26, 2000
APPLICANT Keith L. Black and Nagendra S. Ningaraj			GROUP 1632
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
BH		Ningaraj, N.S., et al., Ca ²⁺ -dependent K ⁺ channels are a key regulatory of blood-brain tumor barrier permeability, Congress of Neurological Surgeons Annual Meeting, 50 th Anniversary Celebration, September 23-28, 2000, Henry B. Gonzalez Convention Center, San Antonio, Texas, ABSTRACT No.428, p. 219.	
BI		Ningaraj, N.S., et al., Nitric oxide donors increase blood-brain tumor barrier permeability via Kca channels, Society for Neuroscience, 30 th Annual Meeting, New Orleans, LA, November 4-9, 2000, 26 Part 1, p. 338, ABSTRACT No. 126.8.	
BJ		Ningaraj, N.S., et al., Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels, The Journal of Pharmacology, June 2002, 301: 838-851	
BK		Pardrige, W., et al., Blood -brain barrier and new approaches to drug delivery, West J Med, 156:281-286 (1992).	
BL		Robertson, B.E., et al., cGMP-dependent protein kinase activates Ca-activated K channels in cerebral artery smooth muscle cells, Am J Physiol, 265:C299-C303 (1993).	
BM		Sobey, C.G., et al., Inhibitory effect of 4-aminopyridine on responses of the basilar artery to nitric oxide, Br J Pharmacol, 126:1437-43 (1999). ABSTRACT ONLY.	
BN		Salom, J.B., et al., Relaxant effects of sodium nitroprusside and NONOates in rabbit basilar artery, Pharmacology, 57:79-97 (1998). ABSTRACT ONLY.	
BO		Salom, J.B., et al., Comparative relaxant effects of the NO donors sodium nitroprusside, DEA/NO and SPER/NO in rabbit carotid arteries, Gen Pharmacol, 32:75-59 (1999). ABSTRACT ONLY.	
BP		Salom, J.B., et al., Relexant effects of sodium nitroprusside and NONates in goat middle cerebral artery: delayed impairment of global ischemia-reperfusion, Nitric Oxide, 3:85-93 (1999). ABSTRACT ONLY.	
BQ		Shukla, A., et al., Nitric oxide-dependent blood-brain barrier permeability alteration in the rat brain, Experientia, 52:136-140 (1996).	
BR		Smolenski, A., et al., Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects, Naunyn-Schmiedeberg's Arch Pharmacol, 358:134-138.	
BS		Sugita, M., et al., Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability in brain tumors, Cancer Research, 58:914-920 (1998).	
BT		Takayasu, M., et al., Effects of calcium antagonists on intracerebral penetrating arterioles in rats, J Neurosurg, 69:104-109 (1988).	
BU		Uchida, M., et al., Overexpression of bradykinin type 2 receptors on glioma cells enhances bradykinin-mediated blood-brain tumor varrier permeability increase, Neurological Research, 24:739-745	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449, Adapted

**LIST OF INFORMATION DISCLOSED BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET NO.		SERIAL NO. 09/491,500	FILING DATE January 26, 2000
APPLICANT Keith L. Black and Nagendra S. Ningaraj		GROUP 1632	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
	BV	Uchida, M., et al., <i>Cyclic GMP-dependent blood-brain tumor barrier permeability is not mediated by cyclic GMP-dependent protein kinase</i> , <u>Congress of Neurological Surgeons Annual Meeting</u> , 50 th Anniversary Celebration, September 23-28, 2000, Henry B. Gonzalez Convention center, San Antonio, Texas, ABSTRACT No. 440, p. 220.	
	BW	Vodovotz, Y., et al., <i>Regulation of transforming growth factor beta 1 by nitric oxide</i> , <u>Cancer Res</u> , 59:2142-9 (1999). ABSTRACT ONLY.	
	BX	Yukabu, M.A., <i>Hematoma-induced enhanced cerebral vasoconstriction to leukotriene C4 and endothelin-1 piglets: role of prostanoids</i> , <u>Pediatr Res</u> , 38:119-23 (1995). ABSTRACT ONLY.	
	BY	Tocris Web Page, http://www.tocris.com/cat/nodonorstxt.html No Donors/Precursors, pp.1-2, Downloaded 5/31/00.	
	BZ	Sigma-Aldrich Web page, http://vsearch.sial.com/search 97cgi/s97-cgi, p.1, downloaded 5/31/00.	
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			